You are here

Article Text

Article menu
Download PDFPDF
Aetiology
Cohort study
Perioperative selective serotonin reuptake inhibitor administration is a marker of poor outcomes after surgery
  1. Natalie F Holt
  1. Department of Anesthesiology, Yale School of Medicine, New Haven, Connecticut, USA
  1. Correspondence to: Dr Natalie F Holt, Department of Anesthesiology, Yale School of Medicine, 333 Cedar Street, TMP 3, New Haven, CT 06520, USA; natalie.holt{at}post.harvard.edu

https://doi.org/10.1136/eb-2013-101491

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Auerbach AD, Vittinghoff E, Maselli J, et al. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med 2013;173:1075–81.OpenUrlCrossRef

    Context

    With a lifetime prevalence of 6–11%, depression is a common comorbidity in surgical patients. Owing to their high efficacy and safety, selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants.1 Some studies suggest that SSRIs may increase surgical bleeding. However, SSRI discontinuation may exacerbate psychiatric illness or precipitate withdrawal symptoms. Therefore, controversy exists over their perioperative management.

    Methods

    Auerbach and colleagues used administrative data from 530 416 patients in 375 US hospitals to determine the association between SSRI use and adverse surgical outcomes. They applied sensitivity analyses and propensity matching to control for the presence of …

    View Full Text

    Footnotes

    • Competing interests None.